Evidence map›Paper›PMID 33151452›Full record

ReviewNeuromolecular medicine2021

Lysophosphatidic Acid Signalling in Nervous System Development and Function.

Eric Birgbauer

Abstract readReview
In one paragraph

Review in Neuromolecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Lysophospholipid receptors in neurodegeneration and neuroprotection.Exploration of neuroprotective therapy · 2024
    Article
  6. Review
  7. Review
  8. Preserving stroke penumbra by targeting lipid signalling.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Eric BirgbauerDepartment of Biology, Winthrop University, Rock Hill, SC, USA. birgbauere@winthrop.edu.ORCID 0000-0002-5555-4970

Funding

South Carolina IDeA Networks of Biomedical Research (SC INBRE V)P20GM103499 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI EDIE C GOLDSMITH · 2012 to 2026
$61.0M
NIGMS NIH HHS P20 GM103499
6 · The paper itself

Abstract

One class of molecules that are now coming to be recognized as essential for our understanding of the nervous system are the lysophospholipids. One of the major signaling lysophospholipids is lysophosphatidic acid, also known as LPA. LPA activates a variety of G protein-coupled receptors (GPCRs) leading to a multitude of physiological responses. In this review, I describe our current understanding of the role of LPA and LPA receptor signaling in the development and function of the nervous system, especially the central nervous system (CNS). In addition, I highlight how aberrant LPA receptor signaling may underlie neuropathological conditions, with important clinical application.

Indexed as

AnimalsAxonsBrainBrain InjuriesCentral Nervous SystemCerebrovascular DisordersDiabetic RetinopathyGlaucomaHumansLysophospholipidsMiceMice, KnockoutNerve Tissue ProteinsNeuralgiaNeural Stem CellsNeurodevelopmental Disorderslysophosphatidic acidLysophospholipidsNerve Tissue ProteinsReceptors, G-Protein-CoupledReceptors, Lysophosphatidic AcidAutotaxinAxon guidanceCortical developmentLPA receptorsLysophospholipidNeuropathic pain

Identifiers

PMID33151452
PMCPMC11420905

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.